1. Home
  2. SLM vs BLLN Comparison

SLM vs BLLN Comparison

Compare SLM & BLLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo SLM Corporation

SLM

SLM Corporation

HOLD

Current Price

$27.95

Market Cap

4.9B

Sector

Finance

ML Signal

HOLD

Logo BillionToOne Inc.

BLLN

BillionToOne Inc.

HOLD

Current Price

$93.15

Market Cap

4.6B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SLM
BLLN
Founded
1972
2016
Country
United States
United States
Employees
N/A
N/A
Industry
Finance: Consumer Services
Medical Specialities
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.9B
4.6B
IPO Year
1997
2025

Fundamental Metrics

Financial Performance
Metric
SLM
BLLN
Price
$27.95
$93.15
Analyst Decision
Buy
Buy
Analyst Count
11
7
Target Price
$31.09
$126.71
AVG Volume (30 Days)
2.6M
786.8K
Earning Date
04-23-2026
05-06-2026
Dividend Yield
2.26%
N/A
EPS Growth
29.10
103.40
EPS
1.85
0.48
Revenue
N/A
$305,112,000.00
Revenue This Year
$3.35
$46.29
Revenue Next Year
$5.68
$30.14
P/E Ratio
$14.99
$195.85
Revenue Growth
N/A
99.97
52 Week Low
$17.77
$61.96
52 Week High
$32.07
$150.44

Technical Indicators

Market Signals
Indicator
SLM
BLLN
Relative Strength Index (RSI) 67.19 34.97
Support Level $26.26 $73.46
Resistance Level $28.38 $99.29
Average True Range (ATR) 0.76 7.36
MACD 0.07 -5.07
Stochastic Oscillator 88.28 6.91

Price Performance

Historical Comparison
SLM
BLLN

About SLM SLM Corporation

SLM Corp is an education solutions company. Its business is to originate and service loans to students and their families to finance the cost of their education. The term' Private Education Loans to mean education loans to students or their families that are not made, insured, or guaranteed by any state or federal government.

About BLLN BillionToOne Inc.

BillionToOne Inc is a molecular diagnostics company. It offers a portfolio of ultrasensitive tests covering prenatal genetic testing, cancer therapy selection, and response monitoring, which are based on its Quantitative Counting Templates (QCT) molecular counting platform. The company's product portfolio comprises UNITY, a portfolio of prenatal testing products that can conduct fetal risk analysis without requiring a paternal sample; Northstar Select, a ultrasensitive liquid biopsy test that provides insights into appropriate therapies for stage III or IV cancer patients; and Northstar Response, a tissue-free, pan-cancer, liquid biopsy test that measures several genomic loci uniquely methylated in cancer to provide insight into dynamic changes in therapy response.

Share on Social Networks: